<DOC>
	<DOCNO>NCT01218958</DOCNO>
	<brief_summary>This Phase 3 , multicenter , randomize , double-blind , placebo-controlled study conduct subject diagnose alcohol dependence define Diagnostic Statistical Manual Mental Disorders , 4th Ed . ( DSM-IV ) . Subjects randomize ( 2:2:1:1 ) receive intramuscular ( IM ) injection Medisorb® naltrexone 190 mg , Medisorb naltrexone 380 mg , placebo Medisorb naltrexone 190 mg , placebo Medisorb naltrexone 380 mg ( VIVITROL® ) . Study drug administer every 4 week total 6 injection .</brief_summary>
	<brief_title>ALK21-003 : Study Medisorb® Naltrexone ( VIVITROL® ) Alcohol-Dependent Adults</brief_title>
	<detailed_description>All subject receive standardized biopsychosocial support therapy ( BRENDA Approach [ Volpicelli , JR [ 2001 ] ; Guilford Press : New York ] ) visit . Subjects complete study ( ie , receive 6 injection study drug complete study visit ) continue meet eligibility criterion give option enroll extension study ALK21-003EXT ( NCT01218971 ) . A second extension , Study ALK21-010 ( NCT00156923 ) , conduct subsequent ALK21-003EXT .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Diagnosis alcohol dependence base Diagnostic Statistical Manual Mental Disorders , 4th Ed . ( DSMIV ) criteria Male nonpregnant , nonlactating female Able provide TimeLine FollowBack ( TLFB ) alcohol consumption information 90day period detoxification and/or screen At least 2 episode heavy alcohol drink per week 30 day detoxification and/or screen Negative urine toxicological screen opiate day randomization Noncustodial , stable residence phone plus 1 contact verifiable address phone Primary Evidence hepatic failure include : ascites , prolong prothrombin time ( PT ) ( international normalize ratio [ INR ] ≥1.7 ) , bilirubin &gt; 10 % upper limit normal ( ULN ) and/or esophageal variceal disease Active hepatitis and/or aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) high 3xULN History pancreatitis Major depression suicidal ideation , psychosis , bipolar disorder , psychiatric disorder would compromise subject 's ability complete study Current dependence ( within past year ) per DSMIV criterion benzodiazepine , opioids cocaine Use benzodiazepine and/or Ambien® ( zolpidem tartrate ) within 7 day prior first dose study medication Greater 7 day inpatient treatment substance use disorder within 30 day randomization Use opioids and/or methadone within 14 day screening , likely require opioid therapy study period Use oral naltrexone disulfiram within 14 day screen Known intolerance and/or hypersensitivity naltrexone , carboxymethylcellulose , polylactidecoglycolide ( PLG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcoholism</keyword>
</DOC>